Taysha Gene Therapies(TSHA) - 2024 Q4 - Annual Results

Clinical Trials - TSHA-102 clinical program has completed dosing of 10 patients in Part A of the REVEAL trials, with 6 in the high dose cohort and 4 in the low dose cohort[5] - The pivotal trial design update for TSHA-102 is anticipated in the first half of 2025[7] - Clinical data from both high and low dose cohorts in the REVEAL trials is expected in the first half of 2025[8][9] Financial Performance - Net loss for the full year 2024 was $89.3 million, or$0.36 per share, compared to a net loss of $111.6 million, or$0.96 per share, in 2023[12] - Research and development expenses for the full year 2024 were $66.0 million, an increase of 16.2$56.8 million in 2023[10] - Total operating expenses for 2024 were $99.8 million, up from$87.9 million in 2023, reflecting increased clinical trial activities[20] Cash and Assets - Cash and cash equivalents as of December 31, 2024, were $139.0 million, expected to support operations into Q4 2026[12] - Total assets decreased to$160.4 million in 2024 from $172.7 million in 2023, primarily due to a reduction in cash and cash equivalents[22] Administrative Expenses - General and administrative expenses decreased to$29.0 million in 2024 from $30.0 million in 2023, a reduction of 3.3$16,000 in 2024, compared to a loss of $34.7 million in 2023[20]